Clinical trials: Non-small-cell Lung Cancer (NSCLC)
Non-squamous Non-small Cell Lung Cancer
Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
The objective of this study is to assess the similarity between QL1101 and Avastin® respectively combined with chemotherapy in terms of efficacy and safety in patients with non-squamous non-small cell lung cancer.
- Trial name
- NCT03169335
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 535 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Non-squamous Cell Non-small Cell Lung Cancer
To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer
To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic…
- Trial name
- NCT03792074
- Testing
- SCT510, Bevacizumab, Paclitaxel
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
Non Small Cell Lung Cancer
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Chemotherapy for patients with non-squamous non-small cell lung cancer. Patients are given folic acid, vitamin B12 and steroids, both before and during treatment, to reduce the side effects associated with pemetrexed.
- Trial name
- NCT00609518
- Testing
- pemetrexed, Folic acid, Vitamin B12
- Where
- 14 sites in Australia, Italy and 2 more
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
NSCLC (Advanced Non-small Cell Lung Cancer), Adaptive Radiotherapy
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
Locally advanced non-small cell lung cancer (LA-NSCLC) patients could benefit in overall and progression-free survival from regular dosimetric treatment plan adaptations during radiotherapy.
- Trial name
- ECLAIR (NCT07259447)
- Testing
- CBCT-based adaptive radiotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Advanced Non-Small Cell Lung Cancer
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
- Trial name
- NCT04922658
- Testing
- Surufatinib, Surufatinib Plus Vinorelbine
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Lung Cancer
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00533585
- Testing
- BAY 43-9006, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Carcinoma, Non-Small-Cell Lung, Docetaxel
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
This study is a randomized, single-center, open-label, phase II clinical trial designed to evaluate non-small cell lung cancer that has failed to undergo excessive platinum-based chemotherapy and has not received excessive statin…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Docetaxel, Nivolumab
- Trial name
- NCT04023617
- Testing
- Nivolumab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Erlotinib and Sunitinib in NSCLC
To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
- Trial name
- NCT00581789
- Testing
- erlotinib, sunitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
To investigate the maximum tolerated dose of BIBF 1120 and safety in escalating doses administered with Vinorelbine i.v. and Carboplatin i.v. in elderly patients with advanced Non-Small Lung Cancer (Stage IV).
- Trial name
- VENUS-2 (NCT01683682)
- Testing
- BIBF 1120, Vinorelbine, Carboplatin
- Where
- 2 sites in Germany
- Volunteers
- 8 people
- Sponsor
- Aktion Bronchialkarzinom e.V.
Non-small Cell Lung Cancer
Pemetrexed/Carboplatin vs Vinorelbine/Carboplatin in Patients With Completely Resected Non-small Cell Lung Cancer (NSCLC)
The main purpose of this randomized phase II trial is to evaluate the clinical feasibility and activity of administering adjuvant chemotherapy of pemetrexed/carboplatin compared with vinorelbine/carboplatin in patients with…
- Trial name
- NCT01258127
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Shanghai Nancy Medical Sci-Tech Co. Ltd
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Lung Cancer, Malignant Mesothelioma
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00020124
- Testing
- doxorubicin hydrochloride
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-small Cell Lung Cancer, NSCLC
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent…
- Trial name
- NCT04746924
- Testing
- Tislelizumab, Ociperlimab, Pembrolizumab
- Where
- 218 sites in United States, Argentina and 17 more
- Volunteers
- 669 people
- Sponsor
- BeiGene
Non-squamous Non-Small Cell Lung Cancer
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1…
- Trial name
- RACE-2L (NCT06491862)
- Where
- 11 sites in Brazil
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer (NSCLC)
The rationale of phase II study of biweekly docetaxel and cisplatin in patients with unresectable NSCLC are follows: First, the optimal dose and schedule of combination with docetaxel and cisplatin are still controversial (3…
- Trial name
- NCT00995761
- Testing
- Docetaxel and Cisplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Gyeongsang National University Hospital
Non-small Cell Lung Cancer
National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.
- Trial name
- NCT03982459
- Testing
- Decision support tool
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC
ALK TKIs, particularly second- and third-generation ALK TKIs, have significantly improved progression-free survival (PFS) in patients with advanced ALK-positive non-small cell lung cancer (NSCLC).
- Trial name
- NCT07671560
- Testing
- Combined group of ensatinib and arotinib
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Qiming Wang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.